人工多能性幹細胞生産市場規模、シェア、成長分析：プロセス別、ワークフロー別、製品別、用途別、最終用途別、地域別 - 産業予測 2025～2032年

人工多能性幹細胞生産の市場規模は2023年に15億3,000万米ドルで、2024年の16億8,000万米ドルから2032年には34億9,000万米ドルに拡大し、予測期間（2025-2032年）のCAGRは9.6%で成長する見通しです。

幹細胞（iPSC）製造市場は、再生医療と細胞治療の分野で目覚ましい成長と革新を遂げています。成体細胞から誘導され、多能性状態に再プログラムされたiPSCは、個別化治療や疾患モデリングに大きな可能性を提供します。この急成長する市場は、創薬や様々な病状におけるiPSCの応用に対する理解の高まりに後押しされています。研究開発とバイオテクノロジー企業は、スケーラブルでコスト効率の高いiPSC生産のための効率的な技術を積極的に開発しています。学界、業界、ヘルスケア機関のコラボレーションが進歩を推進する一方で、厳しい規制の枠組みや倫理的配慮が情勢を形成し、標準化された手法の必要性が浮き彫りになっています。世界のヘルスケアの進化に伴い、iPS細胞製造市場は継続的に拡大し、科学的ブレークスルーと治療ソリューションへの道を開くことになります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢

人工多能性幹細胞生産市場規模：プロセス別& CAGR（2025-2032）

• 市場概要
• マニュアル
• 自動化

人工多能性幹細胞生産市場規模：ワークフロー別& CAGR（2025-2032）

• 市場概要
• 再プログラミング
• 細胞培養

人工多能性幹細胞生産市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 消耗品とキット
• 装置
• サービス

人工多能性幹細胞生産市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 医薬品開発と発見
• 再生医療
• 毒性学研究
• 疾患モデル
• その他

人工多能性幹細胞生産市場規模：最終用途別& CAGR（2025-2032）

• 市場概要
• 学術調査機関
• バイオテクノロジー・製薬会社
• 病院・クリニック

人工多能性幹細胞生産市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• FUJIFILM Cellular Dynamics（USA）
• Astellas Pharma（Japan）
• Thermo Fisher Scientific（USA）
• Takara Bio（Japan）
• Lonza Group（Switzerland）
• Merck KGaA（Germany）
• ReproCELL（Japan）
• STEMCELL Technologies（Canada）
• Fate Therapeutics（USA）
• Cynata Therapeutics（Australia）
• Axol Bioscience（UK）
• Ncardia（Belgium）
• Pluricell Biotech（Brazil）
• Evotec（Germany）
• BioTime（USA）
• Cellular Engineering Technologies（USA）
• StemoniX（USA）
• BrainXell（USA）
• EMD Millipore（USA）
• R&D Systems（USA）

結論と提言

Induced Pluripotent Stem Cells Production Market size was valued at USD 1.53 billion in 2023 and is poised to grow from USD 1.68 billion in 2024 to USD 3.49 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).

The triggered pluripotent stem cell (iPSC) manufacturing market is experiencing remarkable growth and innovation within regenerative medicine and cellular therapy. Derived from adult cells and reprogrammed into a pluripotent state, iPSCs offer significant potential for personalized treatments and disease modeling. This burgeoning market is fueled by an increasing understanding of iPSCs' applications in drug discovery and various medical conditions. Researchers and biotech firms are actively developing efficient techniques for scalable and cost-effective iPSC production. Collaborations among academia, industry, and healthcare institutions are driving advancements, while stringent regulatory frameworks and ethical considerations shape the landscape, highlighting the need for standardized practices. As global healthcare evolves, the iPSC manufacturing market is set for continued expansion, paving the way for scientific breakthroughs and therapeutic solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Induced Pluripotent Stem Cells Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Induced Pluripotent Stem Cells Production Market Segments Analysis

Global Induced Pluripotent Stem Cells Production Market is segmented by Process, Workflow, Product, Application, End-Use and region. Based on Process, the market is segmented into Manual and Automated. Based on Workflow, the market is segmented into Reprogramming and Cell Culture. Based on Product, the market is segmented into Consumables & Kits, Instruments and Services. Based on Application, the market is segmented into Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, Disease Modeling and Others. Based on End-Use, the market is segmented into Academic & Research Institutes, Biotechnology & Pharmaceutical Companies and Hospitals & Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Induced Pluripotent Stem Cells Production Market

A significant driving force behind the global induced pluripotent stem cells (iPSC) production market is the ongoing advancements in regenerative medicine. These stem cells present substantial potential for creating personalized and effective treatments for various medical conditions, thereby attracting significant investment in research and development. Such innovations not only broaden the applications of iPSCs but also present novel therapeutic options, which significantly propel market growth. The increasing interest from pharmaceutical companies and healthcare institutions further enhances this trend, underscoring the pivotal role that advancements in regenerative medicine play in fostering market expansion and stimulating continued investment in iPSC technologies.

Restraints in the Induced Pluripotent Stem Cells Production Market

One significant constraint facing the global induced pluripotent stem cells (iPSC) production market is the array of ethical and regulatory hurdles. Issues regarding the use of human-derived materials, coupled with concerns about the potential misuse of iPSC technology, have led to the implementation of strict regulations in various regions. These obstacles can impede research initiatives, raise compliance costs, and generate market uncertainty. Consequently, such factors can hinder the pace of iPSC adoption and commercialization, ultimately affecting the growth and development of this promising sector in regenerative medicine and biotechnology.

Market Trends of the Induced Pluripotent Stem Cells Production Market

The global Induced Pluripotent Stem Cells (iPSC) production market is witnessing a significant trend driven by the emergence of iPSC-based disease modeling. Researchers and pharmaceutical companies are increasingly leveraging iPSC technology to develop disease-specific cell lines, facilitating more accurate and personalized modeling of a variety of diseases, including genetic disorders, neurodegenerative conditions, and cardiovascular diseases. This shift not only enhances drug discovery and development processes but also fosters the emergence of targeted and effective therapeutic strategies, ultimately shaping the future landscape of precision medicine. As a result, the demand for iPSC products is expected to surge, propelling market growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Induced Pluripotent Stem Cells Production Market Size by Process & CAGR (2025-2032)

• Market Overview
• Manual
• Automated

Global Induced Pluripotent Stem Cells Production Market Size by Workflow & CAGR (2025-2032)

• Market Overview
• Reprogramming
• Cell Culture

Global Induced Pluripotent Stem Cells Production Market Size by Product & CAGR (2025-2032)

• Market Overview
• Consumables & Kits
• Instruments
• Services

Global Induced Pluripotent Stem Cells Production Market Size by Application & CAGR (2025-2032)

• Market Overview
• Drug Development & Discovery
• Regenerative Medicine
• Toxicology Studies
• Disease Modeling
• Others

Global Induced Pluripotent Stem Cells Production Market Size by End-Use & CAGR (2025-2032)

• Market Overview
• Academic & Research Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics

Global Induced Pluripotent Stem Cells Production Market Size & CAGR (2025-2032)

• North America (Process, Workflow, Product, Application, End-Use)
  • US
  • Canada
• Europe (Process, Workflow, Product, Application, End-Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Process, Workflow, Product, Application, End-Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Process, Workflow, Product, Application, End-Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Process, Workflow, Product, Application, End-Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• FUJIFILM Cellular Dynamics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReproCELL (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STEMCELL Technologies (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynata Therapeutics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axol Bioscience (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ncardia (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pluricell Biotech (Brazil)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioTime (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellular Engineering Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• StemoniX (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BrainXell (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Millipore (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• R&D Systems (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations